EFTR - eFFECTOR Therapeutics, Inc. Stock Price, Fair Value and News

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

EFTR Price Action

Last 90 days

-100%

Trailing 12 Months

-100%

EFTR RSI Chart

EFTR Valuation

EV/EBITDA

0.17

EFTR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

EFTR Fundamentals

EFTR Revenue

Revenue (TTM)

3.9M

EFTR Earnings

Earnings (TTM)

-34.6M

Earnings Growth (Yr)

11.78%

Earnings Growth (Qtr)

3.24%

EFTR Profitability

EBT Margin

427.69%

Return on Equity

-4.2K%

Return on Assets

-127.64%

EFTR Investor Care

Shares Dilution (1Y)

177.37%

Diluted EPS (TTM)

-12.67

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q2	Q3	Q4
2022	2.5M	3.6M	3.9M
2021	28.5M	15.0M	1.4M
2020	0	0	42.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

CEO	Dr. Stephen T. Worland Ph.D.
WEBSITE	https://effector.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	15

eFFECTOR Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for eFFECTOR Therapeutics, Inc.? What does EFTR stand for in stocks?

EFTR is the stock ticker symbol of eFFECTOR Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of eFFECTOR Therapeutics, Inc. (EFTR)?

As of Fri Dec 20 2024, market cap of eFFECTOR Therapeutics, Inc. is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EFTR stock?

You can check EFTR's fair value in chart for subscribers.

Is eFFECTOR Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether EFTR is over valued or under valued. Whether eFFECTOR Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact eFFECTOR Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EFTR.

What is eFFECTOR Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, EFTR's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EFTR PE ratio will change depending on the future growth rate expectations of investors.